Valneva (VALN) has released an update.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Valneva SE and LimmaTech Biologics AG have received FDA Fast Track designation for their tetravalent Shigella vaccine candidate, S4V, showcasing significant potential to address a major global health threat. This designation aims to expedite the vaccine’s development and review process to combat the deadly shigellosis disease, which affects millions annually. Valneva plans to advance further development and commercialization of the vaccine worldwide, pending approval.
For further insights into VALN stock, check out TipRanks’ Stock Analysis page.